Skip to main content
Clinical Trials/NCT02845466
NCT02845466
Unknown
Phase 3

Proof of Concept Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing

McMaster University1 site in 1 country80 target enrollmentAugust 2018

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Venous Ulcer
Sponsor
McMaster University
Enrollment
80
Locations
1
Primary Endpoint
Level of Applied Growth Factors in Chronic Wound Fluid
Last Updated
8 years ago

Overview

Brief Summary

Leg and foot ulcers due to venous disease or diabetes are chronic wounds that can take 6 or more months to heal. Growth factors have been used to try and improve this healing, however, many such studies have failed, and that is thought to be due enzymes in the wound that degrade the growth factors and prevent them from working. This is a proof of concept study that will evaluate the treatment of chronic leg ulcers with topically applied growth factors that are combined with a therapy to prevent their inactivation in the wound.

Registry
clinicaltrials.gov
Start Date
August 2018
End Date
September 2020
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Men and women aged ≥18 years
  • Ulcer size 1-64 cm²
  • Ulcer extends through both the epidermis and dermis, with no exposed tendon or bone
  • Ulcer duration \>3 months
  • Ulcer located between and including the knee and ankle
  • For venous leg ulcers - Venous refilling time \<25s on photoplethysmography or abnormal venous insufficiency Duplex scan
  • For diabetic foot ulcers - confirmed type 1 or type 2 diabetes mellitus with a haemoglobin A1C \< 12%
  • Wounds have not been treated with Promogran in the previous 4 weeks
  • Patients able to give informed consent

Exclusion Criteria

  • Ankle-brachial index \<0.8
  • Ulcer with local or systemic signs of infection
  • Patients who have been previously treated with Becaplermin gel
  • Receiving corticosteroids or immune suppressants
  • History of autoimmune disease
  • Uncontrolled diabetes (baseline haemoglobin A1C \> 12%)
  • Severe rheumatoid arthritis
  • Uncontrolled congestive heart failure
  • Malnutrition (albumin \<2.5g/dL)
  • Unable to adhere to the protocol

Outcomes

Primary Outcomes

Level of Applied Growth Factors in Chronic Wound Fluid

Time Frame: 6 weeks

The levels of the growth factors applied to the chronic wound will be measured using samples of the wound fluid gathered at the first two visits each week.

Secondary Outcomes

  • Protease Levels in Chronic Wound Fluid(6 weeks)
  • Chronic Wound Healing at 4 Weeks(4 weeks)
  • WOUNDCHEK Device Validity(6 weeks)
  • Levels of Healing Biomarkers in Chronic Wound Fluid(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials